Louis Lavigne - Novocure Independent Director
| NVCR Stock | USD 12.34 0.28 2.32% |
Director
Mr. Louis J. Lavigne, Jr. is an Independent Director of the Company. Mr. Lavigne was a director of Novocure since 2012 and has served as the chairperson of our audit committee since 2012. Mr. Lavigne is currently the Managing Director of Lavrite, LLC, a management consulting firm specializing in corporate finance, accounting, growth strategy and management, and is also the managing member of Spring Development Group, LLC, a specialized investor in growth situations. Mr. Lavigne retired in March 2005 as Executive Vice President and Chief Financial Officer of Genentech, Inc., where he had served in roles of increasing responsibility since 1982. He currently serves on the boards of Accuray, Inc., Depomed, Inc., DocuSign, Inc., Zynga, Inc., Rodan Fields, LLC, and Puppet, Inc. Mr. Lavigne also previously served on the boards of Allergan, Inc., BMC Software, Inc., and SafeNet, Inc. Mr. Lavigne is a member and former chairman of the UCSF Benioff Childrens Hospitals Board of Directors and the UCSF Benioff Childrens Hospitals Foundation since 2012.
| Age | 69 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Address | No. 4 The Forum, Saint Helier, Jersey, JE2 4UF |
| Phone | 44 15 3475 6700 |
| Web | https://www.novocure.com |
Novocure Management Efficiency
The company has return on total asset (ROA) of (0.1209) % which means that it has lost $0.1209 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5153) %, meaning that it created substantial loss on money invested by shareholders. Novocure's management efficiency ratios could be used to measure how well Novocure manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/25/2024, Return On Tangible Assets is likely to drop to -0.19. In addition to that, Return On Capital Employed is likely to drop to -0.25. At this time, Novocure's Non Current Assets Total are relatively stable compared to the past year. As of 04/25/2024, Non Currrent Assets Other is likely to grow to about 14.7 M, while Net Tangible Assets are likely to drop slightly above 267.8 M.Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.12 |
Novocure Leadership Team
Elected by the shareholders, the Novocure's board of directors comprises two types of representatives: Novocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novocure. The board's role is to monitor Novocure's management team and ensure that shareholders' interests are well served. Novocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Hung, Director | ||
| Sherilyn McCoy, Director | ||
| William Vernon, Independent Director | ||
| William Burke, Chief Officer | ||
| Frank Leonard, Executive Oncology | ||
| Asaf Danziger, CEO and Director | ||
| Kinyip Leung, Vice Chairman and Chairman of The Global Commercialization Team | ||
| Timothy Langloss, Independent Director | ||
| Piet MD, Head VP | ||
| Moshe Giladi, Chief Officer | ||
| Pr MD, Founder CTO | ||
| MBA MD, Chief Officer | ||
| Eilon Kirson, Chief Science Officer and Head of Research and Development | ||
| Todd Longsworth, General Counsel | ||
| Ingrid Goldberg, VP Relations | ||
| Charles Phillips, Independent Director | ||
| Louis Lavigne, Independent Director | ||
| Barak Arye, General Counsel | ||
| William Burkoth, Independent Director | ||
| Michael Ambrogi, COO | ||
| Martin Madden, Independent Director | ||
| Michael Puri, Chief Officer | ||
| Robert Mylod, Independent Director | ||
| Yoram Palti, CTO, Director | ||
| Uri MD, Chief Officer | ||
| Pritesh Shah, Chief Commercial Officer | ||
| Ashley Cordova, Chief Officer | ||
| Wilhelmus Groenhuysen, Chief Officer | ||
| Jeryl Hilleman, Director | ||
| Gert Perlhagen, Independent Director | ||
| Peter Melnyk, Chief Commercial Officer | ||
| William Doyle, Executive Chairman |
Novocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.34) % | ||||
| Current Valuation | 984.86 M | ||||
| Shares Outstanding | 107.61 M | ||||
| Shares Owned By Insiders | 9.30 % | ||||
| Shares Owned By Institutions | 85.73 % | ||||
| Number Of Shares Shorted | 5.01 M | ||||
| Price To Earning | 721.15 X |
Novocure Investors Sentiment
The influence of Novocure's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novocure. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novocure's public news can be used to forecast risks associated with an investment in Novocure. The trend in average sentiment can be used to explain how an investor holding Novocure can time the market purely based on public headlines and social activities around Novocure. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novocure's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novocure's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novocure's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novocure.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novocure in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novocure's short interest history, or implied volatility extrapolated from Novocure options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novocure. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.Note that the Novocure information on this page should be used as a complementary analysis to other Novocure's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Novocure Stock analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Novocure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share (1.95) | Revenue Per Share 4.787 | Quarterly Revenue Growth 0.042 | Return On Assets (0.12) |
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.